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data by education level from the Bureau of Labor Statistics to the WPAI scores. Work 
productivity and indirect social cost were compared across patient sociodemographic 
characteristics and disease severity. RESULTS: A total of 191 MS patients were evalu-
ated at baseline with 114 working either full-time (78.1%) or part-time (21.9%). In 
this working sample, 75.4% were females, 72.8% were married, 71.1% were below 
50 years old and a majority were White (88.5%). The overall productivity loss due 
to MS among full-time employed patients and part-time employed patients was 42.5% 
(SD: 26.9) and 42.1% (SD: 30.6), respectively. This translates into a substantial pro-
ductivity loss of 17 hours of loss time in a 40-hour work-week for full-time workers 
and 8.4 hours of loss time in a 20-hour work week for part-time workers. At average 
wages, this productivity loss equates to an indirect annual social loss of $18,106 per 
patient (SD: $13,265) among full-time workers and $8,871 per patient (SD: $7,080) 
among part-time workers. Indirect social costs were signiﬁcantly correlated with 
increasing MS severity (r  0.21; p  0.0.029). CONCLUSIONS: Multiple sclerosis 
results in a substantial loss of work productivity among patients, which collectively 
results in signiﬁcant indirect social cost. The MS-related indirect social costs increase 
with increasing MS severity.
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OBJECTIVES: This study compares the result of cost estimation for glaucoma outpa-
tients using micro-costing and gross-costing methods. It also examines the factors 
contributing to the difference in results and investigates the impact of the result by 
costing method on Budget Impact Analysis(BIA). METHODS: Per year costs of glau-
coma outpatients were estimated for micro-costing, which consists of medical fee, eye 
examinations and laser therapy. A decision tree designed with 6 pathways was used. 
A patient’s visit frequency and transition probability for each pathway were obtained 
from literature and clinical expert opinions. In gross-costing, yearly per-capita outpa-
tient average costs were calculated by using health insurance statistics data on glau-
coma (ICD 10 code: H40). For BIA, each costing result was applied to the patients 
nationwide. RESULTS: The calculated costs of annual outpatient were $148.7 and 
$71.1 for micro-costing and gross-costing, respectively. The cost calculated by 
pathway in micro-costing ranged from the minimum of $142.9 to the maximum of 
$589.8. BIA result were $11,302,788 for micro-costing and $5,407,527 for gross-
costing. CONCLUSIONS: One factor contributing to the difference between the two 
methods is the gap between the standard model and the actual use of medical services. 
Another factor particular to gross-costing is that in the case a patient changes medical 
institutions, data from previous institutions do not accumulate, which underestimates 
the total cost of medical care. As a result, different costing methods may result in dif-
ferent decision-making of new drugs.
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Most previous work estimating survival rates for diabetes has been based on logistic 
regression or standardized ratios to derive odds ratios rather than being based on 
survival analysis with risk estimates over time. Few studies have estimated the excess 
risk between those with and without diabetes. OBJECTIVES: The purpose of this 
study was to estimate the excess risk and cumulative relative risks of death and com-
plications between those with newly diagnosed diabetes and those without. 
METHODS: Newly diagnosed type 1 and 2 diabetes cases aged 35 and over were 
identiﬁed from the Ontario Diabetes Database and matched 1:2 using propensity 
scores with controls (non-diabetes cases). Using linked provincial administrative data-
bases, data on death and the following complications were recorded: myocardial 
infarction, stroke, angina, heart failure, blindness, amputation, nephropathy and cata-
ract. Kaplan Meier curves were calculated to estimate the probability of being event-
free for those with and without diabetes for up to 10 years of follow-up. RESULTS: 
A total of 610,852 patients aged 35 and over with diabetes were matched with 
1,221,704 patients without diabetes. For those with diabetes vs. those without, there 
was a statistically signiﬁcant increased relative risk at 10 years for death (1.417, [95%] 
CI 1.415–1.418), myocardial infarction (2.094, [95%] CI 2.092–2.095), stroke 
(1.877, [95%] CI 1.874–1.879), angina (1.526, [95%] CI 1.525–1.527), heart failure 
(2.520, [95%] CI 2.529–2.522), amputation (6.824, [95%] CI 6.823–6.824), 
nephropathy (2.902, [95%] CI 2.901–2.904), blindness (1.212, [95%] CI 1.205–
1.218) and cataract (1.326, [95%] CI 1.324–1.327). CONCLUSIONS: Diabetes 
is a signiﬁcant health problem with excess risk of death and complications typically 
associated with diabetes. Using estimates of risk of death or complications for a 
general (non-diseased) population can result in signiﬁcant underestimates of disease 
burden or cost-effectiveness in decision analytic models of disease management or 
prevention.
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OBJECTIVES: To assess the persistence of type-2 diabetic patients treated with basal 
supported oral therapy (BOT) with insulin glargine (GLA) compared to NPH insulin 
(NPH). METHODS: We performed a retrospective cohort study using claims data for 
ambulatory prescriptions within the German statutory health-insurance scheme, based 
on a representative sample of more than 80 % of German community pharmacies. 
Insulin-naive patients treated with oral antidiabetic drugs (OAD) who were addition-
ally initiating therapy with GLA or NPH between January 2003 and December 2006 
were included and followed up until December 2007. Persistence was deﬁned as the 
duration of time from initiation of GLA or NPH until switching to intensiﬁed con-
ventional insulin therapy (ICT). A switch to ICT was assumed whenever a short-acting 
insulin was prescribed for the ﬁrst time followed by at least one prescription of a 
long-acting insulin within six months. Univariate and multivariate Cox proportional 
hazards models were used to compare both cohorts. RESULTS: In total, 97,998 
patients (61,070 Glargine and 36,928 NPH) were included. Within the observation 
period, 23.5 % of GLA patients and 28.0 % of NPH patients switched to ICT. On 
average, these patients stayed 388 days on GLA and 313 days on NPH, respectively 
(p  0.001, log-rank test). The risk of switching to ICT was signiﬁcantly higher for 
NPH patients compared to GLA patients (unadjusted hazard ratio [HR] 1.34 (99 % 
CI: 1.29–1.38)). After adjustment for predeﬁned covariables i.e., type of physician 
(general practitioner vs. specialist), region, insurance status (member, family member, 
retired), health insurance company, comedication, number of OAD, dose of basal 
insulin, the risk for NPH patients remained signiﬁcantly higher (adjusted HR: 1.22 
(99 % CI: 1.18–1.27). CONCLUSIONS: Type 2 diabetic patients under basal sup-
ported oral therapy treated with insulin glargine stay signiﬁcantly longer on initial 
therapy until they switch to ICT when compared to NPH.
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OBJECTIVES: To assess the prevalence of potentially undiagnosed diabetes mellitus 
(UDM) in a nationally representative patient sample. METHODS: The data source 
was GE’s Medical Quality Improvement Consortium (MQIC) database (February 
2009) containing electronic medical record (EMR) data on 11 million patients in the 
U.S. Two previously published (Holt, et al, 2008) search strategies were applied to 
identify patients without diagnosis or medication evidence of DM, but with a fasting 
(FBG) or random blood glucose (RBG) result available (denominator for prevalence 
estimates). Strategy A patients were non-DM patients whose last glucose on record 
(LGOR)  RBG q11.1 or FBG q7.0 mmol/l. Strategy B patients were non-DM 
patients with LGOR (FBG or RBG) q7.0 mmol/l. Strategy A and B patients were each 
grouped by age/sex categories, and prevalence of UDM calculated. The time since 
LGOR to datacut date was also assessed. RESULTS: From 11,196,881 total patients, 
923,007 had diagnosed DM on record (n  570,723) or were presumed to have DM 
on the basis of prescribed oral hypoglycemics or insulin (n  352,284). After exclud-
ing additional patients with gestational diabetes and impaired glucose tolerance/pre-
diabetes,10,147,355 remained. Of these, 3,799,599 had a glucose result available, 
with 38,068 identiﬁed as possible UDM using Strategy A (prevalence 0.38%), and 
221,624 using Strategy B (prevalence 2.18%). In both instances, UDM prevalence 
increased with increasing age, in both sexes. Over 2 years had elapsed since the 
LGOR for over 50% of Strategy A patients, and 40% of Strategy B patients. 
CONCLUSIONS: The application of simple search algorithms to a large EMR data-
base suggests there may be substantial underdiagnosis of DM in the US general 
population.
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OBJECTIVES: To evaluate the risk of stroke or myocardial infarction (MI) in patients 
with type-2 diabetes mellitus (T2DM) receiving pioglitazone (PIO) or non-thiazolidin-
edione (Non-TZD) therapies. METHODS: A analysis of I3 Innovus database from 
January 1, 2000 to June 30, 2007 was conducted. T2DM patients (ICD-9 diagnosis 
codes 250.x0 or 250.x2) were grouped into PIO or Non-TZD cohorts based on the 
study drugs initiated. The index date is the ﬁrst dispensing of pioglitazone or Non-
TZD medications. Follow-up started at the index date and ended upon disenrollment 
from the health plan, ﬁrst occurrence of stroke or MI, or the end of the period, 
